Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
Patients treated with dupilumab had marked and rapid improvement in all the evaluated measures of atopic dermatitis disease activity, and side-effect profiles were not dose-limiting.
Th17 cytokines interleukin (IL)‐17 and IL‐22 modulate distinct inflammatory and keratinocyte‐response pathways
- K. Nograles, Lisa C. Zaba, J. Krueger
- Medicine, BiologyBritish Journal of Dermatology
- 1 November 2008
This data indicates that suppression of Th1 and Th17 cytokines in Psoriasis vulgaris is a pro-inflammatory disease and the relative contribution of interferon, IFN,γ, interleukin and IL‐22 on disease pathogenesis is still unknown.
IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells.
- K. Nograles, Lisa C. Zaba, E. Guttman-Yassky
- Biology, MedicineJournal of Allergy and Clinical Immunology
- 1 June 2009
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
- E. Simpson, T. Bieber, M. Ardeleanu
- MedicineNew England Journal of Medicine
- 30 September 2016
Dupilumab improved the signs and symptoms of atopic dermatitis, including pruritus, symptoms of anxiety and depression, and quality of life, as compared with placebo in two phase 3 trials of identical design.
Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis.
- J. Gittler, A. Shemer, E. Guttman-Yassky
- Biology, MedicineJournal of Allergy and Clinical Immunology
- 1 December 2012
Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis.
- A. Chiricozzi, E. Guttman-Yassky, J. Krueger
- BiologyJournal of Investigative Dermatology
- 1 March 2011
The data predict that Psoriasis therapy with either TNF or IL-17 antagonists will produce greater modulation of the synergistic/additive gene set, which consists of the most highly expressed genes in psoriasis skin lesions.
Atopic dermatitis endotypes and implications for targeted therapeutics.
- T. Czarnowicki, H. He, J. Krueger, E. Guttman-Yassky
- BiologyJournal of Allergy and Clinical Immunology
- 2019
Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis.
- E. Guttman-Yassky, M. Lowes, J. Krueger
- Biology, MedicineJournal of Allergy and Clinical Immunology
- 1 May 2007
Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials
- E. Simpson, J. Lacour, K. Reich
- Medicine, BiologyBritish Journal of Dermatology
- 29 January 2020
Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced atopic dermatitis (AD) severity in a phase II study with concomitant topical corticosteroids.
Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?
- E. Guttman-Yassky, J. Krueger
- Biology, MedicineCurrent Opinion in Immunology
- 1 October 2017
...
...